Transition to Pentacel® from Pediacel® vaccine in the publicly funded immunization program

Advisory Alert

April 8, 2024

*Cette information est seulement disponible en anglais.

To: Local Health System Partners


Pentacel® is replacing Pediacel® as the DTaP-IPV-Hib vaccine provided through the publicly funded immunization program

Please be advised that Sanofi Vaccines Canada is discontinuing manufacture of the Pediacel® vaccine and will be transitioning to Pentacel® vaccine.

During the transition period, doses of Pediacel® vaccine can still be used until the expiration date. You can expect to see Pentacel® vaccine in your orders in late April or early May as our current inventory of Pediacel® vaccine is depleted. You may see both products in your vaccine orders during the early part of the product transition.

Important considerations

Pentacel® and Pediacel® vaccines are both pentavalent vaccines used to protect against diphtheria, tetanus, pertussis, polio and Haemophilius influenzae type b (DTaP-IPV-Hib) in children from 2 months to 6 years of age (prior to their 7th birthday).

Although there are some notable differences between the two products including how they are packaged and prepared for administration, they are equivalent and interchangeable products. Important considerations are noted below. The product monograph is attached for your reference.

Pentacel® vaccine packaging
Pentacel® vaccine preparation
Pentacel® administration

Children presenting to you who have received one or more previous doses of Pediacel® vaccine can have their vaccine series completed with Pentacel®, in accordance with current guidelines from the National Advisory Committee on Immunization (NACI). Previous doses of Pediacel® are valid and the series does not need to be restarted. The number of doses of vaccine and the specific product required for series completion depends on the child’s age and immunization history. Refer to the Ontario Publicly Funded Immunization Schedule for further information.

Sanofi will be sending a Notification of Transition to the medical community along with a general questions and answers document.

Should you have additional questions, please contact us as outlined below.

Contact Public Health Sudbury & Districts


Original Signed By

M. Mustafa Hirji MD, MPH, FRCPC
Acting Medical Officer of Health and Chief Executive Officer

NOTE: All Advisory Alerts are found on our website.

This item was last modified on April 12, 2024